CNTBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Connect Biopharma Holdings Ltd
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.90−0.01 (-0.72%)
Close on Oct 19, 2026
- Market cap
- $56.58M
- P/E (TTM)
- –
- Dividend yield
- –
Connect Biopharma Holdings Ltd income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -2384.5%
- Net margin
- -2336.3%
- Return on equity, FY2025
- -82.7%
Financial strength
- Current ratio
- 2.37
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 165.7%
Valuation
- P/E ratio
- –
- Price to sales
- 19.16
- Price to book
- 2.11
- Dividend yield
- –